Fig. 3From: Management of Persistent Epistaxis Using Floseal Hemostatic Matrix vs. traditional nasal packing: a prospective randomized control trial95% Confidence ellipses of bootstrapped incremental costs and incremental effects from both health system and societal perspectives (cost-effectiveness plane). Legend: *point estimate residing in the right lower quadrant indicates that the treatment (i.e. Floseal® (Baxter, USA)) is by definition, cost-effective and dominant)Back to article page